pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

atox-bio PRESS RELEASE ARCHIVE

Dec 10, 2020

Atox Bio Announces FDA Acceptance to File the NDA for Reltecimod to Treat Suspected Organ Dysfunction or Failure in Patients with Necrotizing Soft Tissue Infection ("Flesh-Eating Disease") USA - English Israel - English

Jun 18, 2019

Atox Bio Announces Exercise by BARDA of Next Option Period to Support Continued Development of Reltecimod for NSTI

Jun 18, 2019

Atox Bio Announces Exercise by BARDA of Next Option Period to Support Continued Development of Reltecimod for NSTI

Feb 14, 2019

Atox Bio Announces Appointment of Robert Greif as Chief Commercial Officer

Feb 14, 2019

Atox Bio Announces Appointment of Robert Greif as Chief Commercial Officer

Sep 25, 2018

Atox Bio Announces Independent Safety Monitoring Committee Recommendation to Continue Phase 3 Study of Reltecimod in Necrotizing Soft Tissue Infections

May 29, 2018

Atox Bio Announces Enrollment of First Patient in Phase 2 Study of Acute Kidney Injury (AKI)

Dec 4, 2017

Atox Bio Closes $30 Million Investment

Sep 25, 2017

Atox Bio Awarded Next Milestone-based Option by BARDA to Support Continued Development of Reltecimod for Necrotizing Soft Tissue Infections

May 23, 2017

Atox Bio's Reltecimod Passes Futility Analysis in Phase 3 ACCUTE Study; Trial Continues as Planned

Nov 3, 2016

Atox Bio Announces Independent Safety Monitoring Committee Recommendation to Continue Phase 3 Study Of AB103 In Necrotizing Soft Tissue Infections

Jun 15, 2016

Atox Bio Awarded Next Milestone-based Option by BARDA to Support Development of AB103 for Necrotizing Soft Tissue Infections

Dec 7, 2015

Atox Bio Enrolls First Patient in Phase 3 Study of Potential Treatment for Necrotizing Soft Tissue Infection (Flesh Eating Bacteria)

Apr 16, 2015

Atox Bio Announces Oral Presentation at the 35th Annual Meeting of the Surgical Infection Society

Dec 15, 2014

Atox Bio Announces Appointment of Biotech Veteran Daniel D. Burgess as Chairman of the Board

Sep 29, 2014

Atox Bio Awarded Contract Worth up to $24 Million for the Development of AB103 by the Biomedical Advanced Research and Development Authority (BARDA)

Jul 24, 2014

Atox Bio Closes $23 Million Investment

Apr 9, 2013

Atox Bio Publishes Data Demonstrating the Broad Therapeutic Effect of its Flagship Product in Treating “Flesh Eating Bacteria”

Nov 20, 2012

Atox Bio Announces Positive Top Line Results in the AB103 Necrotizing Soft Tissue Infections (NSTI) Phase 2a Trial

Sep 10, 2012

FDA grants Fast Track designation to Atox Bio’s AB103 for the treatment of necrotizing soft tissue infections (NSTI)

Dec 19, 2011

Atox Bio Raises $3.25 million to Advance Development of AB103, a Novel Therapy for the Treatment of Severe Bacterial Infections, Currently in Phase 2 Clinical Trials

Oct 25, 2011

Atox Bio Granted Orphan Drug Designation for AB103 for the Treatment of Necrotizing Soft Tissue Infections (NSTI).

May 12, 2011

Atox Bio Announces Successful Completion of Phase 1 for AB103, a Novel Immunomodulator Being Developed for Severe Bacterial Infections and Sepsis.

Google Analytics Alternative